M&As this week: Serum Institute of India, Fresenius, NanoCarrier

US-based biopharmaceutical company Nanotherapeutics has been acquired by Serum Institute of India.

Based in India, the acquirer company develops and manufactures drugs. Serum Institute has paid €45m ($48.85m) as an upfront payment for the €72m ($78.17m) acquisition, while the remaining consideration will be paid a year later.

The acquisition is expected to help the Indian company to create a unit for polio vaccine injectables.

German healthcare company Fresenius has reached an agreement to acquire Akorn for $4.3bn.

"German healthcare company Fresenius has reached an agreement to acquire Akorn for $4.3bn."

The acquirer company will also assume the target company’s net debt of approximately $450m.

Akorn is a generic pharmaceutical company based in the US, whose acquisition is expected to complement Fresenius’ medicines division.

NanoCarrier, a company based in Japan, is set to acquire US-based Tocagen.

Both companies involved in the acquisition are biotechnology firms.